派姆单抗-话题@MedSci

#派姆单抗#

82篇内容 | 3715人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1253484, encodeId=eee21253484b3, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=NEJM：派姆单抗治疗持续性、复发性或转移性宫颈癌的效果如何？, objectType=article, longId=220141, objectId=193c220141f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=193c220141f9, replyNumber=0, likeNumber=116, createdTime=2021-11-12, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=193c220141f9, moduleTitle=NEJM：派姆单抗治疗持续性、复发性或转移性宫颈癌的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=193c220141f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253483, encodeId=e5c9125348377, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=JCO：派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响, objectType=article, longId=219785, objectId=78b3219e858a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78b3219e858a, replyNumber=0, likeNumber=112, createdTime=2021-11-06, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78b3219e858a, moduleTitle=JCO：派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78b3219e858a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253482, encodeId=ced512534821d, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Eur J Cancer：使用派姆单抗治疗的晚期黑色素瘤患者的长期结局, objectType=article, longId=218034, objectId=095b21803441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=095b21803441, replyNumber=0, likeNumber=74, createdTime=2021-10-03, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=095b21803441, moduleTitle=Eur J Cancer：使用派姆单抗治疗的晚期黑色素瘤患者的长期结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=095b21803441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253481, encodeId=f472125348160, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Clin Cancer Res：标准剂量的派姆单抗联合不同剂量的伊匹单抗治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=217050, objectId=249821e0501a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249821e0501a, replyNumber=0, likeNumber=79, createdTime=2021-09-15, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249821e0501a, moduleTitle=Clin Cancer Res：标准剂量的派姆单抗联合不同剂量的伊匹单抗治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249821e0501a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253480, encodeId=c00f125348077, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=抗生素是否对接受派姆单抗的肌层浸润膀胱癌患者有危害？, objectType=article, longId=216721, objectId=e2d6216e214c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2d6216e214c, replyNumber=0, likeNumber=78, createdTime=2021-09-07, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2d6216e214c, moduleTitle=抗生素是否对接受派姆单抗的肌层浸润膀胱癌患者有危害？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2d6216e214c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253479, encodeId=415512534e919, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, objectType=article, longId=216311, objectId=0e3021631188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3021631188, replyNumber=0, likeNumber=98, createdTime=2021-08-27, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3021631188, moduleTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3021631188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253478, encodeId=a39012534e86e, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=NEJM：肾癌患者肾切除术后辅助派姆单抗疗效分析, objectType=article, longId=216008, objectId=79ac21600839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79ac21600839, replyNumber=0, likeNumber=95, createdTime=2021-08-21, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79ac21600839, moduleTitle=NEJM：肾癌患者肾切除术后辅助派姆单抗疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79ac21600839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253477, encodeId=9feb12534e7ec, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Clin Cancer Res：Motixafortide+派姆单抗+化疗在预后不良的胰腺导管腺癌中展现出治疗活性, objectType=article, longId=215843, objectId=f9c721584330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9c721584330, replyNumber=0, likeNumber=103, createdTime=2021-08-18, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9c721584330, moduleTitle=Clin Cancer Res：Motixafortide+派姆单抗+化疗在预后不良的胰腺导管腺癌中展现出治疗活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9c721584330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253476, encodeId=69da12534e696, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, objectType=article, longId=214810, objectId=c1e621481097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e621481097, replyNumber=0, likeNumber=75, createdTime=2021-07-27, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e621481097, moduleTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e621481097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253475, encodeId=331012534e562, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, objectType=article, longId=214063, objectId=7ac421406392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac421406392, replyNumber=0, likeNumber=88, createdTime=2021-07-13, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac421406392, moduleTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac421406392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253474, encodeId=a3a712534e4d1, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！, objectType=article, longId=212814, objectId=199e212814dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199e212814dc, replyNumber=0, likeNumber=91, createdTime=2021-06-18, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199e212814dc, moduleTitle=Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199e212814dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253473, encodeId=a13912534e323, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Immunother Cancer：所有肿瘤患者都可以用相同剂量的派姆单抗治疗吗？, objectType=article, longId=212464, objectId=96b221246426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96b221246426, replyNumber=0, likeNumber=98, createdTime=2021-06-10, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96b221246426, moduleTitle=J Immunother Cancer：所有肿瘤患者都可以用相同剂量的派姆单抗治疗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96b221246426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253472, encodeId=4b0a12534e2c7, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet Oncol：派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效, objectType=article, longId=211961, objectId=5b9821196102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b9821196102, replyNumber=0, likeNumber=88, createdTime=2021-05-29, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b9821196102, moduleTitle=Lancet Oncol：派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b9821196102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253471, encodeId=964112534e1b4, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！, objectType=article, longId=211950, objectId=274d2119505a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=274d2119505a, replyNumber=0, likeNumber=65, createdTime=2021-05-29, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=274d2119505a, moduleTitle=Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=274d2119505a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253470, encodeId=1b8412534e07f, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, objectType=article, longId=211288, objectId=122f21128838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122f21128838, replyNumber=0, likeNumber=85, createdTime=2021-05-15, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122f21128838, moduleTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122f21128838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253469, encodeId=a7a61253469cf, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！, objectType=article, longId=210240, objectId=c7a6210240c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a6210240c2, replyNumber=0, likeNumber=90, createdTime=2021-04-22, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a6210240c2, moduleTitle=JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a6210240c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253468, encodeId=8e1d12534686a, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet Oncol：派姆单抗辅助治疗可显著提高晚期高危黑色素瘤的长期无远处复发存活率！, objectType=article, longId=209912, objectId=e3e920991243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3e920991243, replyNumber=0, likeNumber=82, createdTime=2021-04-15, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3e920991243, moduleTitle=Lancet Oncol：派姆单抗辅助治疗可显著提高晚期高危黑色素瘤的长期无远处复发存活率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3e920991243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253467, encodeId=0f3f125346ef3, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=J Immunother Cancer：抗生素对派姆单抗治疗的NSCLC患者的预后具有显著的负性效应！, objectType=article, longId=209752, objectId=c7c0209e52a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7c0209e52a2, replyNumber=0, likeNumber=86, createdTime=2021-04-11, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7c0209e52a2, moduleTitle=J Immunother Cancer：抗生素对派姆单抗治疗的NSCLC患者的预后具有显著的负性效应！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7c0209e52a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253466, encodeId=b18c1253466f9, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼, objectType=article, longId=209719, objectId=aeac209e1906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeac209e1906, replyNumber=0, likeNumber=68, createdTime=2021-04-10, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeac209e1906, moduleTitle=NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeac209e1906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253465, encodeId=cead12534650c, content=<a href='/topic/show?id=1c4e65265d5' target=_blank style='color:#2F92EE;'>#派姆单抗#</a>, objectTitle=Lancet respirat med：派姆单抗单药治疗晚期间皮瘤的疗效分析, objectType=article, longId=209709, objectId=6bf2209e091f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bf2209e091f, replyNumber=0, likeNumber=108, createdTime=2021-04-10, rootId=0, userName=jianjun66, userId=ce5632, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bf2209e091f, moduleTitle=Lancet respirat med：派姆单抗单药治疗晚期间皮瘤的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bf2209e091f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

派姆单抗

2020-05-29

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

NEJM：派姆单抗治疗持续性、复发性或转移性宫颈癌的效果如何？

2021-11-12

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

JCO：派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响

2021-11-06

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Eur J Cancer：使用派姆单抗治疗的晚期黑色素瘤患者的长期结局

2021-10-03

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Clin Cancer Res：标准剂量的派姆单抗联合不同剂量的伊匹单抗治疗晚期黑色素瘤的疗效和安全性

2021-09-15

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

抗生素是否对接受派姆单抗的肌层浸润膀胱癌患者有危害？

2021-09-07

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果

2021-08-27

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

NEJM：肾癌患者肾切除术后辅助派姆单抗疗效分析

2021-08-21

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Clin Cancer Res：Motixafortide+派姆单抗+化疗在预后不良的胰腺导管腺癌中展现出治疗活性

2021-08-18

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！

2021-07-27

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性

2021-07-13

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！

2021-06-18

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Immunother Cancer：所有肿瘤患者都可以用相同剂量的派姆单抗治疗吗？

2021-06-10

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet Oncol：派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效

2021-05-29

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！

2021-05-29

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性

2021-05-15

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

JCO：派姆单抗一线疗法治疗转移性NSCLC患者的5年预后明显优于化疗！

2021-04-22

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet Oncol：派姆单抗辅助治疗可显著提高晚期高危黑色素瘤的长期无远处复发存活率！

2021-04-15

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

J Immunother Cancer：抗生素对派姆单抗治疗的NSCLC患者的预后具有显著的负性效应！

2021-04-11

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼

2021-04-10

jianjun66 (审核中...)

前往app查看评论内容

#派姆单抗#

Lancet respirat med：派姆单抗单药治疗晚期间皮瘤的疗效分析

2021-04-10

科室
- - 订阅+
  - 更多科室
工具
服务